171 related articles for article (PubMed ID: 25058044)
1. l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors.
Pendolino V; Bagetta V; Ghiglieri V; Sgobio C; Morelli E; Poggini S; Branchi I; Latagliata EC; Pascucci T; Puglisi-Allegra S; Calabresi P; Picconi B
Exp Neurol; 2014 Nov; 261():377-85. PubMed ID: 25058044
[TBL] [Abstract][Full Text] [Related]
2. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
3. Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism.
Bonito-Oliva A; Pignatelli M; Spigolon G; Yoshitake T; Seiler S; Longo F; Piccinin S; Kehr J; Mercuri NB; Nisticò R; Fisone G
Biol Psychiatry; 2014 May; 75(9):701-10. PubMed ID: 23541633
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of D1/D5 receptors prevents long-term depression (LTD) and learning-facilitated LTD at the perforant path-dentate gyrus synapse in freely behaving rats.
Wiescholleck V; Manahan-Vaughan D
Hippocampus; 2014 Dec; 24(12):1615-22. PubMed ID: 25112177
[TBL] [Abstract][Full Text] [Related]
5. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Gubellini P; Eusebio A; Oueslati A; Melon C; Kerkerian-Le Goff L; Salin P
Eur J Neurosci; 2006 Sep; 24(6):1802-14. PubMed ID: 17004943
[TBL] [Abstract][Full Text] [Related]
6. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
J Neurosci; 2015 Oct; 35(41):14057-69. PubMed ID: 26468205
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
8. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Jeon MY; Lee WY; Kang HY; Chung EJ
Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Chiu WH; Depboylu C; Hermanns G; Maurer L; Windolph A; Oertel WH; Ries V; Höglinger GU
Neuropharmacology; 2015 Aug; 95():367-76. PubMed ID: 25839898
[TBL] [Abstract][Full Text] [Related]
10. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Glavan G
Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
12. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
13. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
Holden H; Venkatesh S; Budrow C; Nezaria S; Coyle M; Centner A; Lipari N; McManus G; Bishop C
Physiol Behav; 2024 Jul; 281():114563. PubMed ID: 38723388
[TBL] [Abstract][Full Text] [Related]
14. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Sciaccaluga M; Mazzocchetti P; Bastioli G; Ghiglieri V; Cardinale A; Mosci P; Caccia C; Keywood C; Melloni E; Padoani G; Vailati S; Picconi B; Calabresi P; Tozzi A
Neuropharmacology; 2020 Jun; 170():108024. PubMed ID: 32142791
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
16. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
17. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Alam M; Mayerhofer A; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
[TBL] [Abstract][Full Text] [Related]
18. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Ferrario JE; Rojas-Mayorquín AE; Saldaña-Ortega M; Salum C; Gomes MZ; Hunot S; Raisman-Vozari R
J Neurochem; 2008 Oct; 107(2):443-52. PubMed ID: 18752647
[TBL] [Abstract][Full Text] [Related]
19. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
[TBL] [Abstract][Full Text] [Related]
20. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Buck K; Ferger B
Synapse; 2010 Feb; 64(2):117-26. PubMed ID: 19771592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
